Life Science News

Resorts World Las Vegas Secures First-of-its-Kind Agreement With Allergan Aesthetics

Multiyear Agreement Makes Allergan Aesthetics the Preferred Aesthetics and Rewards Partner of the new World-Class Resort

**For approved photos, click here **

Resorts World Las Vegas and Concerts West / AEG Presents have entered into a first-of-its-kind agreement with Allergan Aesthetics, an ABBVie company (NYSE: ABBV), to become the preferred aesthetics and rewards partner for Resorts World Las Vegas. As part of the multiyear agreement brokered by AEG Global Partnerships and Resorts World Las Vegas, Allergan Aesthetics will have exclusive branding rights to the property's 66 th floor lounge, now known as Allē Lounge on 66, and Resorts World Theatre's VIP meet-and-greet space, Allē Backstage. This is the first official partnership with entitlement of this kind at Resorts World Las Vegas which opened in June 2021. This agreement represents Allergan Aesthetics' first-ever branding of a specific area at a major resort and live entertainment venue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005756/en/

Allē Backstage's Allē Lounge on 66 at Las Vegas' Resorts World Theatre (Photo: Business Wire)

Allē Backstage's Allē Lounge on 66 at Las Vegas' Resorts World Theatre (Photo: Business Wire)

"Allergan Aesthetics' consumer loyalty program, Allē, is disrupting the aesthetics space by offering the most robust rewards program in the industry," said Heidi Shurtz, Associate Vice President, Integrated Marketing and Promotions, Allergan Aesthetics. "With partnerships like this we are truly creating consumer engagement in a way that has never been done before within aesthetics. We plan to continue to pursue meaningful partnerships like this for the benefit of our loyal consumers."

The newly named Allē Lounge on 66 will provide Allergan Aesthetics the ability to introduce millions of annual visitors to its portfolio of products and treatments. Located on the 66 th floor of Las Vegas' newest resort, Allē Lounge on 66 offers guests an impressive meeting space to connect and relax in a luxe setting. Allē is curating unique consumer experiences, engaging guests with brand-tailored, on-site activations and promotions at the Lounge that offers guests sweeping views of the famed Las Vegas Strip.

"Allergan Aesthetics is an ideal partner for Resorts World Las Vegas as the company continues to break barriers in its industry and also shares our vision of bringing new and exciting experiences to our guests," said Scott Sibella, President of Resorts World Las Vegas. "This first-of-its-kind partnership will allow us to leverage our common audiences and create synergies that will take our brands to the next level."

With Allē Backstage, located inside Resorts World Theatre , Allergan Aesthetics solidifies its position as a category leader, not only across Las Vegas, but also amongst some of the most passionate live music and entertainment fans who will be visiting from around the world each year. With Allē Backstage, Allergan Aesthetics will engage select premium fans, headlining artists and VIP guests through various activations throughout the space.

"We are proud to welcome Allergan Aesthetics, an internationally renowned category leader as our newest partner," said John Nelson, Senior Vice President of AEG Presents Las Vegas. "Their commitment to excellence matches ours and together, we look forward to adding to the guest experience at Resorts World Las Vegas while bringing world-class live entertainment and enhanced fan experiences to visitors of our state-of-the-art theatre."

"Resorts World Las Vegas has quickly become one of the most exciting destinations on the Las Vegas Strip and we're thrilled to have Allergan Aesthetics by our side as we continue to bring this incredible venue to life," said Erin Zinser, Vice President of AEG Global Partnerships. "AEG has a very successful and long-standing relationship with Allergan Aesthetics, so we knew this partnership would be a natural fit from the start. We look forward to collaborating on innovative new fan experiences and growing live entertainment in Las Vegas together for years to come."

ABOUT ALLERGAN AESTHETICS

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com .

ABOUT Allē℠

Allē℠ is the next generation of Allergan Aesthetics' loyalty rewards program, Brilliant Distinctions®. With Allē, consumers unlock access to curated content, exclusive offers, and personalized rewards for the Allergan Aesthetics™ leading portfolio of products that can be redeemed at their provider's office.

ABOUT RESORTS WORLD LAS VEGAS

Resorts World Las Vegas was developed by Genting Berhad, a publicly traded Malaysian corporation registered with the Nevada Gaming Commission. The company has affiliated operations in the Americas, Malaysia, Singapore, the United Kingdom and the Bahamas. In partnership with Hilton, Resorts World Las Vegas integrates three of Hilton's premium brands into its resort campus, including Las Vegas Hilton, the resort's full-service brand; Conrad Las Vegas, Hilton's lifestyle luxury brand; and LXR, Hilton's network of independent luxury properties, which operates as Crockfords Las Vegas, Genting's internationally renowned ultra-luxury brand. Resorts World Las Vegas features 3,506 guest rooms and suites, an innovative, next-generation gaming floor, world-class food and beverage options, a 5,000-capacity theatre, distinct nightlife venues, a curated retail collection of designer and boutique shops and more. The integrated resort weaves time-honored traditions of the international Resorts World brand into the fabric of Las Vegas, introducing a bold, fresh take on hospitality to the city with stunning design, progressive technology and world-class guest service. Resorts World Las Vegas is Sharecare Health Security VERIFIED™ with Forbes Travel Guide, a verification that ensures the resort has appropriate health safety procedures in place. For more information, visit rwlasvegas.com or find us on Facebook , LinkedIn , Twitter and Instagram .

ABOUT AEG PRESENTS

Combining the power of the live event with a focus on true artist development, AEG Presents is a world leader in the music and entertainment industries. Operating across four continents, the company has an unparalleled commitment to artistry, creativity, and community. Its tentpole festivals and multi-day music events — which include the iconic Coachella Valley Music & Arts Festival and the legendary New Orleans Jazz & Heritage Festival alongside British Summer Time at Hyde Park, Stagecoach, Hangout Festival, Electric Forest, and Firefly — continue to set the bar for the live music experience. AEG Presents promotes global tours for artists such as The Rolling Stones, Ed Sheeran, Elton John, Taylor Swift, Celine Dion, Justin Bieber, Kenny Chesney, Paul McCartney, and Katy Perry, in addition to — through its network of clubs, theatres, arenas, stadiums and renowned partner brands such as Goldenvoice, Messina Touring Group, Concerts West, The Bowery Presents, PromoWest Productions, Marshall Arts, Madison House Presents, and Zero Mile Presents — creating and developing an unmatched infrastructure for artist development and audience reach. More information can be found at www.aegpresents.com or find us on Facebook , Twitter and Instagram.

Media Contacts:
Alison Brod Marketing + Communications
(for Resorts World Las Vegas)
Emily Kjesbo, Emilyk@abmc-us.com

AEG
Michael Roth, MRoth@AEGWorldwide.com

BECK Media & Marketing
(for AEG Global Partnerships)
Shannon Donnelly, Shannon.Donnelly@BECKMedia.com

News Provided by Business Wire via QuoteMedia

ABBV
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona's patents for TFC-1067 and related family of compounds.

"We are very pleased to have finalized terms with a global leader in medical aesthetics and the innovator behind SkinMedica™, a leader in the science of skin rejuvenation," said Dr. Howard Verrico, CEO of Sirona Biochem. "Our most recent clinical trial of TFC-1067 was a collaborative effort with Allergan Aesthetics to demonstrate the clinical potential in topical skin care treatments. This further validates our platform technology as viable for additional commercial products which we are actively pursuing. We would like to thank Dr. Linda Pullan of Pullan Consulting who assisted with our current success."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis

CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–The Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) has adopted a positive opinion
recommending the granting of a marketing authorization for ZINBRYTA™
(daclizumab) intended for the treatment of relapsing forms of multiple
sclerosis (RMS), Biogen
(NASDAQ: BIIB) and AbbVie (NYSE:
ABBV) announced today. ZINBRYTA is a once-monthly, self-administered,
subcutaneous investigational treatment for RMS. ZINBRYTA is also
currently under regulatory review in the United States, Switzerland,
Canada and Australia.
For people with relapsing forms of MS (RMS) and active disease,
ZINBRYTA has the potential to offer robust efficacy, a manageable safety
profile through patient monitoring, and once-monthly subcutaneous
dosing,” said Alfred Sandrock, M.D., Ph.D., executive vice president and
chief medical officer at Biogen. “ZINBRYTA may offer another option for
people with multiple sclerosis (MS) with its targeted mechanism of
action (MOA) which did not cause broad and prolonged immune cell
depletion.”
The CHMP positive opinion is now referred to the European Commission
(EC), which grants marketing authorizations for centrally authorized
medicines in the European Union. A decision from the EC is expected
within the coming months.
Together with Biogen, AbbVie is committed to meeting the needs of
patients with MS, and the positive opinion issued by the CHMP is a
critical step that moves us closer to bringing ZINBRYTA to patients in
Europe,” said Michael Severino, M.D., executive vice president, research
and development and chief scientific officer, AbbVie.
According to the CHMP opinion, the benefits of ZINBRYTA are its ability
to reduce the annualized relapse rate (ARR), as well as the risk of
24-week confirmed disability progression. The opinion is based on
results from two clinical trials, DECIDE and SELECT, in which ZINBRYTA
150 mg, administered subcutaneously every four weeks improved results on
key measures of MS disease activity in patients with RMS compared to
AVONEX 30 mcg intramuscular injection administered weekly and placebo,
respectively.
In the DECIDE study, the overall incidence of adverse events was similar
in the ZINBRYTA and AVONEX groups. In patients treated with ZINBRYTA
compared to AVONEX, there was an increased incidence of serious
infections (4% versus 2%), serious cutaneous reactions (2% versus <1%),
elevations of liver transaminases greater than five times the upper
limit of normal (6% versus 3%), gastrointestinal disorders (31% versus
24%), and depression (8% versus 6%).
About ZINBRYTA™ (daclizumab)
ZINBRYTA (daclizumab) is an investigational compound being developed for
the treatment of relapsing forms of MS. ZINBRYTA is a new form of a
humanized monoclonal antibody that selectively binds to the
high-affinity interleukin-2 (IL-2) receptor subunit (CD25) that is
expressed at high levels on T-cells that become activated in people with
MS. ZINBRYTA modulates IL-2 signaling without general immune cell
depletion.
Biogen and AbbVie are jointly developing ZINBRYTA.
About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops
and delivers worldwide innovative therapies for people living with
serious neurological, autoimmune and rare diseases. Founded in 1978,
Biogen is one of the world’s oldest independent biotechnology companies
and patients worldwide benefit from its leading multiple sclerosis and
innovative hemophilia therapies. For more information, please visit www.biogen.com.
Follow us on Twitter.
Biogen Safe Harbor
This press release contains forward-looking statements, including
statements about the anticipated timing of the EC’s decision on the
marketing authorization for ZINBRYTA, and potential impact of ZINBRYTA,
if approved. These statements may be identified by words such as
“believe,” “expect,” “may,” “potential,” “will” and similar expressions,
and are based on our current beliefs and expectations. You should not
place undue reliance on these statements. Drug development and
commercialization involve a high degree of risk. Factors which could
cause actual results to differ materially from our current expectations
include the risk that the EC may fail to approve or may delay approval
of ZINBRYTA or may not follow the recommendation of the CHMP,
uncertainty of success in commercialization of ZINBRYTA For more
detailed information on the risks and uncertainties associated with our
drug development and commercialization activities and risks relating to
our collaborations with third parties, please review the Risk Factors
section of our most recent annual or quarterly report filed with the
Securities and Exchange Commission. Any forward-looking statements speak
only as of the date of this press release and we assume no obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in
2013 following separation from Abbott Laboratories. The company’s
mission is to use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address some of
the world’s most complex and serious diseases. Together with its
wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000
people worldwide and markets medicines in more than 170 countries. For
further information on the company and its people, portfolio and
commitments, please visit www.abbvie.com.
Follow @abbvie on
Twitter or view careers on our Facebook or LinkedIn
page.
Forward-Looking Statements
Some statements in this news release may be forward-looking statements
for purposes of the Private Securities Litigation Reform Act of 1995.
The words “believe,” “expect,” “anticipate,” “project” and similar
expressions, among others, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially from those indicated in the forward-looking
statements. Such risks and uncertainties include, but are not limited
to, challenges to intellectual property, competition from other
products, difficulties inherent in the research and development process,
adverse litigation or government action, and changes to laws and
regulations applicable to our industry.
Additional information about the economic, competitive, governmental,
technological and other factors that may affect AbbVie’s operations is
set forth in Item 1A, “Risk Factors,” in AbbVie’s 2014 Annual Report on
Form 10-K, which has been filed with the Securities and Exchange
Commission. AbbVie undertakes no obligation to release publicly any
revisions to forward-looking statements as a result of subsequent events
or developments, except as required by law.

Enbrel Biosimilar Marks Victory for Merck and Samsung

The biosimilar alliance between Merck (NYSE:MRK) and Samsung Bioepis appears to have paid off, as the companies have won South Korean approval for their copy of Amgen’s (NASDAQ:AMGN) blockbuster drug Enbrel.
According to Fierce Biotech:

Korea’s Ministry of Food and Drug Safety signed off on the injection, to be marketed as Brenzys, to treat rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and psoriasis in adults. The biosimilar, developed as SB4, proved itself equivalent to Amgen’s cash cow in a 596-patient study disclosed this year, reducing symptoms of rheumatoid arthritis on pace with its reference product, according to Merck and Samsung.
Brenzys’ approval marks the first marketing victory for the two companies, a milestone Merck hopes will be a harbinger of future success in biosimilars.
The approval could also have major implications for Samsung Bioepis, long rumored to be considering a U.S. IPO. Details of the company’s Wall Street plans have been tricking out for months, and The Wall Street Journal reported in August that Samsung is planning a $1 billion debut offering for its biologics division, valuing the company at about $7 billion.
Samsung Bioepis, a joint venture with Biogen ($BIIB) that is 85% owned by the South Korean company, joined forces with Merck in 2013 in a wide-ranging deal designed to crack the growing market for off-patent biological treatments. Beyond Enbrel, the pair are working on copies of the similar Humira from AbbVie ($ABBV) and Remicade from Johnson & Johnson ($JNJ). The companies are also developing biosimilars of Sanofi’s ($SNY) blockbuster insulin Lantus and Roche’s ($RHHBY) cancer treatment Herceptin.

Keep reading...Show less

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval.

About Gilead Sciences

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022

Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

Now Offers Patients the Choice of Administration at Home or in a Doctor's Office

Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE ® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. 1 First approved by the FDA in December 2021 TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g., eosinophilic or allergic) or biomarker limitation within its approved label. 2-9

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

  • Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion
    • Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange
    • Full-Year Revenues from In-Line Products and New Product Portfolio were $35.4 Billion, an Increase of 9%, or 13% When Adjusted for Foreign Exchange
  • Posts Fourth Quarter GAAP EPS of $0.95 and Non-GAAP EPS of $1.82; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
  • Reports Full-Year GAAP EPS of $2.95 and Non-GAAP EPS of $7.70; Includes Net Impact of ($0.24) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
  • Provides GAAP and Non-GAAP Financial Guidance for 2023 Reflecting Continued Revenue and Earnings Growth

Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

Toward Health Equity Oncology Grant ™ Supports Initiatives to Break the Cycle of Health Inequity –

Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™. The funding will support evidence-based interventions that address barriers to care and social determinants of health including patient navigator training, cultural competency training, and services combating barriers such as transportation.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST

- Amgen ( NASDAQ : AMGN ) posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier today.

The transcript, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Audio of the webcast will also be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×